Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563317 | 0.86 | KIF11 (0.41) | MAPK1CYP2D6DRD3CYP3A4ALDH1A1 | |
| SCHEMBL1592771 | 0.82 | JAK2 (0.44) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL7030622 | 0.81 | MAPK1 (0.46) | MAPK1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL14059543 | 0.81 | CYP2D6 (0.42) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL11044204 | 0.79 | KIF11 (0.52) | MAPK1CYP2D6DRD3CYP3A4ALDH1A1 | |
| SCHEMBL1021158 | 0.79 | GRM1 (0.49) | MAPK1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL5875525 | 0.79 | MAPK1 (0.44) | MAPK1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL6225960 | 0.78 | MAPK1 (0.48) | MAPK1CYP3A4ALDH1A1TAAR1ALOX15 | |
| SCHEMBL307338 | 0.77 | TSHR (0.52) | ALDH1A1ATMESR1ESR2GRM1 | |
| SCHEMBL20629458 | 0.77 | CYP2D6 (0.42) | MAPK1CYP2D6DRD2DRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279982-B | Binder for silicon-based negative electrode and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-106380441-B | Synthetic method of fexofenadine intermediate | 上海雅本化学有限公司 | 2020-08-14 | — | — | CN | claimed |
| CN-109809962-A | A kind of new synthetic method of 2- (4- bromomethyl) phenylpropionic acid | 盘锦格林凯默科技有限公司 | 2019-05-28 | — | — | CN | claimed |
| EP-3194569-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | Agency For Science, Technology And Research (SG) | 2017-07-26 | — | — | EP | claimed |
| CN-106380441-A | Synthetic method of fexofenadine intermediate | 上海雅本化学有限公司 | 2017-02-08 | — | — | CN | claimed |
| WO-2016043666-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-24 | — | — | WO | claimed |
| JP-2007512250-A | — | — | 2007-05-17 | — | — | JP | claimed |
| US-7183305-B2 | Process for the synthesis of imidazoles | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | claimed |
| EP-1682517-A1 | PROCESS FOR THE SYNTHESIS OF IMIDAZOLES | Allergan, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005047267-A1 | PROCESS FOR THE SYNTHESIS OF IMIDAZOLES | ALLERGAN, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101785-A1 | Process for the synthesis of imidazoles | ALLERGAN, INC. | 2005-05-12 | — | — | US | claimed |
| EP-0924196-B1 | Process for the alkylation of alkyl- or benzonitrile in the presence of trialkyl amines or phosphines | AVENTIS PHARMA GMBH (DE) | 2003-06-18 | — | — | EP | claimed |
| US-6143896-A | ALKYLATION OF NITRILE COMPOUND WITH SUBSTITUTED OR UNSUBSTITUTED ALKYL HALIDE OR DIALKYLSULFATE IN PRESENCE OF TRIALKYLOR ARYL AMINE OR PHOSPHINE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-07 | — | — | US | claimed |
| EP-0924196-A1 | Process for the alkylation of alkyl- or benzonitrile in the presence of trialkyl amines or phosphines | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-06-23 | — | — | EP | claimed |
| JP-11263766-A | — | — | None | — | — | JP | disclosed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| US-20260116910-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-0349195-A2 | Direct synthesis by cationic polymerization of nitrogen-containing polymers | EXXON CHEMICAL PATENTS INC. (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4787933-A | Herbicide compositions containing a nitrile derivative as antidote | ESZAKMAGYARORSZAGI VEGYIMUVEK (HU) | 1988-11-29 | — | — | US | disclosed |
| US-4136156-A | HYDROGEN CYANIDE, HYDROGENATION CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101785-A1 | Process for the synthesis of imidazoles | LSS, SI, NISCH | MAPK1 1084/4885CYP2D6 230/4885DRD2 1990/4885 |
| US-20260116910-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | NR1H3, NR1H2, CPT1A | MAPK1 2603/4885CYP2D6 565/4885DRD2 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.